Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: A status report

Bone Marrow Transplantation

Volumn 25, Issue 5, 2000, Pages 465-470

  Gertz, M A ^a   Lacy, M Q ^a   Dispenzieri, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloid; Amyloidosis; Chemotherapy; Nephrotic syndrome; Transplantation

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MYELOABLATIVE AGENT; PREDNISOLONE; PREDNISONE; VINCRISTINE;

AMYLOIDOSIS; DIGESTIVE SYSTEM PERFORATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY FAILURE; MORTALITY; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUDDEN DEATH; SURVIVAL;

EID: 0034012359     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702178     Document Type: Review

References (37)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
2. Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93: 1062-1066.
3. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
4. Cohen HJ, Lessin LS, Halal J, Burkholder P. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome. Ann Intern Med 1975; 82: 466-473.
5. Horne MK III. Improvement in amyloidosis (letter). Ann Intern Med 1975; 83: 281-282.
6. Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290-298.
7. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New Engl J Med 1997; 336: 1202-1207.
8. Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 1994; 24: 124-138.
9. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257-262.
10. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl J Med 1984; 310: 1353-1356.
11. Wardley AM, Jayson GC, Goldsmith DJ et al. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 1998; 78: 774-776.
12. Case DC Jr, Lee DJ III, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977; 63: 897-903.
13. Oken MM, Harrington DP, Abramson N et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79: 1561-1567.
14. Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262-267.
15. van Buren M, Hene RJ, Verdonck LF et al. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995; 122: 508-510.
16. Hawkins PN, Aprile C, Capri G et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 1998; 25: 701-708.
17. Gillmore JD, Davies J, Iqbal A et al. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 1998; 100: 226-228.
18. Guillaume B, Straetmans N, Jadoul M et al. Allogeneic bone marrow transplantation for AL amyloidosis. Bone Marrow Transplant 1997; 20: 907-908.
19. Moreau P, Milpied N, de Faucal P et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement (letter). Blood 1996; 87: 3063-3064.
20. Comenzo RL, Michelle D, LeBlanc M el al. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion 1998; 38: 60-69.
21. Lokhorst HM, Verdonck LF. Intensive therapy in AL amyloidosis and light-chain deposition disease (reply to letter). Ann Intern Med 1995; 123: 553.
22. Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801-2806.
23. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-3670.
24. Comenzo RL, Falk RH. Sanchorawala V et al. Treating AL amyloidosis (AL) with dose-intensive melphalan: outcomes in 102 patients (abstract). Blood 1998; 92: 324A.
25. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 1-7.
26. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766-769.
27. Gillmore JD, Apperley JF, Craddock C et al. High-dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA (eds). Amyloid and Amyloidosis 1998. Parthenon Publishing: Pearl River, New York, 1999, pp 102-104.
28. Amoura Z, Leblond V, Azar N et al. High-dose therapy and autologous stem cell transplantation (ASCT) for systemic amyloidosis (AL): report of 9 cases (abstract). Arthritis Rheum 1998; 41: S234.
29. Desikan KR, Dhodapkar MV, Hough A et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997; 27: 315-319.
30. Ager S, Mahendra P, Jestice HK et al. The use of non-cryopreserved peripheral blood progenitor cells in autologous transplantation (letter). Bone Marrow Transplant 1995; 16: 633-634.
31. Mehta J, Nagler A, Slavin S. Marrow transplantation in multiple myeloma (letter). New Engl J Med 1992; 326: 1087.
32. Mujolino I, Marceno R, Pecoraro G et al. Autologous stem cell transplantation in amyloidosis AL (letter). Bone Marrow Transplant 1993; 11: 85.
33. Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 1997; 99: 245-256.
34. Akpek G, Colarusso T, Lerner A et al. Immune reconstitution after autologous blood stem cell transplantation (ABSCT) in patients with AL amyloidosis (AL). Blood 1998; 92: 360B (Abstr.).
35. Kuzmi MA, Schey SA. Morbidity associated with high dose therapy in primary amyloidosis. In: Kyle RA, Gertz MA (eds). Amyloid and Amyloidosis 1998. Parthenon Publishing: Pearl River, New York, 1999, pp 169-171.
36. Gertz M, Lacy M, Gastineau D et al. Blood stem cell transplantation as initial therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant (in press).
37. Dispenzieri A, Lacy MQ, Kyle RA et al. AL amyloidosis is a favorable independent prognostic factor for survival of 234 patients with primary systemic amyloidosis (AL) functionally eligible for peripheral blood stem cell transplantation. Proc ASCO 1999; 18: 20a (Abstr.).